Key regions: Australia, Italy, France, South Korea, Brazil
The Vaccines market in Slovenia has been experiencing significant growth in recent years.
Customer preferences: Slovenia has a high vaccination rate, with the majority of the population being vaccinated against common diseases. The country has a comprehensive national vaccination program that covers a wide range of diseases, including measles, mumps, rubella, and hepatitis B. The government provides free vaccinations to all citizens, and the program has been successful in reducing the incidence of these diseases.
Trends in the market: The vaccines market in Slovenia has been growing steadily over the past few years. This growth can be attributed to various factors, including the increase in the number of people who are aware of the benefits of vaccines and the rise in the number of infectious diseases. Furthermore, the COVID-19 pandemic has had a significant impact on the market, with an increased demand for vaccines and a heightened awareness of the importance of vaccination.
Local special circumstances: Slovenia has a well-developed healthcare system, which has contributed to the success of the national vaccination program. The country has a high level of healthcare spending per capita, and the government is committed to providing high-quality healthcare services to its citizens. Additionally, Slovenia has a strong pharmaceutical industry, with several local manufacturers producing vaccines for both domestic and international markets.
Underlying macroeconomic factors: The growth of the vaccines market in Slovenia is also influenced by several macroeconomic factors. The country has a stable political environment and a well-developed economy, which has contributed to the growth of the healthcare sector. Furthermore, the aging population in Slovenia has led to an increase in the demand for healthcare services, including vaccines. The government has also implemented several policies to encourage the growth of the pharmaceutical industry, such as tax incentives and subsidies for research and development.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
